1 / 14

Measuring and scoring cardiac autonomic neuropathy : a first comparison in diabetes

Measuring and scoring cardiac autonomic neuropathy : a first comparison in diabetes. M. Fevre-Genoulaz M.J. Lafitte S.S. Srikanta. Aim of the study.

emmet
Télécharger la présentation

Measuring and scoring cardiac autonomic neuropathy : a first comparison in diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Measuring and scoring cardiac autonomic neuropathy : a first comparison in diabetes M. Fevre-Genoulaz M.J. Lafitte S.S. Srikanta

  2. Aim of the study Compare the classification of cardiac autonomic neuropathy (CAN) given by standard autonomic scoring and by a new device : the ANSiscopeTM (Dyansys) in healthy volunteers and in diabetic patients

  3. Study population • 21 type 2 diabetic patients (mean age=50+/-9 yrs). 4 of them had complications due to diabetes : retinopathy, and hypertension • 9 non-diabetic volunteers (mean age 38 +/-9 yrs)

  4. Exclusion criteria • Causes of autonomic neuropathy other than diabetes • History of psychoactive drug or alcohol abuse • Cardiac arrythmia

  5. Methods • Each patient underwent 2 sets of tests : • Autonomic tests • ANSiscopeTM autonomic dysfunction test

  6. Autonomic tests • RSA : respiratory sinus arrythmia • Ratio RR inspiration/RR expiration • Valsalva manoeuver • Ratio longest RR/shortest RR • Systolic blood pressure response to standing • Difference between SBP before and 2 min after standing. • 30:15 ratio • Ratio 30th RR int./15th RR int.

  7. Autonomic tests scoring • Scoring is made following description of Bellavere et al. For each test results are classified as being : • Normal = 0 • Borderline = 1 • Abnormal = 2 • The points are added and final score is interpreted as : • 0 and 1 = healthy • Between 2 and 4 = early CAN • 5 and upper = advanced CAN

  8. Assessment of autonomic scoring • minimum 30 minutes of testing • 45 minutes of signal analysis • Complete patient participation • Trained medical team

  9. Measurement with the ANSiscopeTM • This device extracts from the RR intervals (recorded with 3 leads ECG) the activity of the sympathetic and parasympathetic systems on a beat by beat basis. • Measurement of dysautonomia is expressed as a lack of coupling between both activites. Result is expressed as a percentage and a group classification.

  10. Measurement conditions with the ANSiscopeTM • A recording of 572 RR intervals is needed (around 5-7 minutes) • Patient must be at rest in supine condition without external stimulation (which may activate sympathetic system).

  11. Classification group • The nature of the groups : aggregation of values • Values demarcating groups • -11.5 to 11.5 : healthy group • 13.5 to 20 : early group • 23 to 50.99 : late group • 51 to 100 : advanced group healthy early late advanced

  12. Results • Number of patients / groups (H = healthy, E = Early, L = late, A = Advanced), (mean average of dysautonomia percentage +/- Std) • Autonomic scoring detected 2 groups of patients : healthy and early CAN • ANSiscopeTM detected 4 stages of CAN in the same set of patients from healthy to most advanced CAN. • If we consider in the ANSiscopeTM classification 2 groups of patients : (healthy + early) and (late + advanced), we obtain :

  13. Results • Non diabetic and diabetic populations have the same proportion of H and E with autonomic scoring • All patients classified with L and A CAN with the ANSiscope have a mean diabetes duration of 7 yrs which predisposes them to CAN. • All diabetics patients with complications are in L + A group. • Some patients without clinical symptoms are in L+A group, these patients may be considered as being at risk to develop complications due to diabetes.

  14. Conclusion • These first results suggest that the ANSiscopeTM allows to detect precociously CAN and classify patients accurately compared to autonomic scoring. • Method is simple, quick and does not require particular training, it thus represents a good tool to measure autonomic neuropathy in clinical practice. • Further studies need to be performed on larger population.

More Related